Aim: The oral mucosa possesses a non-neuronal cholinergic system. This study aimed to determine clinical evidence for a role of cholinergic mechanisms in the pathogenesis of periodontal diseases.
| INTRODUC TI ON
The role of non-neuronal acetylcholine (ACh) as a cytotransmitter is well established (Wessler & Kirkpatrick, 2008) . Choline acetyltransferase ACh is extremely labile due to the action of esterases (Klapproth et al., 1997) . In humans, acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) are responsible for the hydrolysis of acetylcholine to acetic acid and free choline (Grando, Kist, Qi, & Dahl, 1993) .
The oral mucosa can be defined as having a non-neuronal cholinergic system (Arredondo et al., 2003; Macpherson et al., 2014; Nguyen et al., 2000; Zoheir, Lappin, & Nile, 2012) due to the fact it expresses ChAT, acetylcholine receptors and cholinesterases (Rana et al., 2010; Wessler & Kirkpatrick, 2008) . Roles for non-neuronal ACh within mucosal tissues include; cell proliferation and differentiation, cytoskeletal organization, cell-cell contact, maintenance of effective barrier functions, controlling ion and water movements and modulation of immune responses Wessler & Kirkpatrick, 2008) .
The role of ACh as an immunomodulatory neuroendocrine mediator first came to prominence with the discovery of the "cholinergic anti-inflammatory pathway" (Borovikova et al., 2000) . In this pathway, signals transmitted by parasympathetic nervous system induce the activation and release of ACh by a novel choline acetyltransferase positive (ChAT + ) T cell subset which subsequently downregulates proinflammatory cytokine expression by localised macrophages in the spleen via the α7 nicotinic receptor (α7nAChR) (Martelli, Farmer, & Yao, 2016; Rosas-Ballina et al., 2011) . ChAT + T cells can also emigrate to peripheral sites and mediate parasympathetic anti-inflammatory effects within mucosal tissues (Dhawan et al., 2016) . ChAT + B cell populations in the intestinal mucosa have also been found to release ACh upon antigen stimulation which in turn modulates neutrophil recruitment (Reardon et al., 2013) . Furthermore, oral keratinocytes have been found to release ACh in response to stimulation by Porphyromonas gingivalis and the α7nAChR on oral keratinocytes has been demonstrated to downregulate P. gingivalis induced expression of IL-8 (CXCL8) . The evidence therefore suggests that
ACh can modulate innate immune responses within the oral mucosa and subsequently the pathogenesis of periodontal diseases (Zoheir et al., 2012) .
In vivo models have demonstrated a role for cholinergic systems in the pathogenesis of inflammatory diseases (Hoover, 2017) .
However, there is a fundamental lack of clinical studies associating ACh or cholinesterase activity with disease outcomes. ACh levels have been associated with diseases of impaired cognitive function (Jia et al., 2004; Yamada, Otsuka, Fujimoto, Kawashima, & Yoshida, 1996) and, with respect to the oral cavity, one study demonstrated that ACh levels in gingival tissue are elevated during inflammation (Rajeswari & Satyanarayana, 1990) . Furthermore, cholinesterase activity has been measured in saliva to determine its use as a diagnostic marker of Alzheimer's disease (Sayer, Law, Connelly, & Breen, 2004) .
To date, however, no studies have investigated whether cholinergic mediators are associated with periodontal diseases. Therefore, the aim of this study was to determine whether ACh and esterase activity could be measured in saliva and GCF and determine their relationship with levels of immunoregulatory mediators and clinical outcomes of periodontal diseases.
| MATERIAL S AND ME THODS

| Ethics
The study was conducted in full accordance with ethical principles, including the World Medical Association Declaration of Helsinki, and was approved by the Ethics Committee of the School of Dentistry, Aristotle University of Thessaloniki (AUTh), Greece (9/28.01.2014).
| Study population
A total of 151 individuals were recruited from either patients attending the Lab of Preventive Dentistry, Periodontology and Implant Biology for periodontal treatment, or from faculty members and postgraduate students, at AUTh. Probing pocket depth (PPD); clinical attachment levels (CAL); bleeding on probing (BOP) and plaque indices (PI) were determined at six sites per tooth by a calibrated single examiner (AI). PPD and CAL were measured using an electronic constant-force (15 g pressure) probe (FP32, software version 9; Florida Probe Corporation©, Florida, USA) to the nearest 0.2 mm.
Inclusion criteria: (a) Periodontitis patients (n = 49) having at least two sites per quadrant with PPD and CAL >5 mm and radiographic evidence of bone loss; (b) Gingivitis patients (n = 52)
presenting with BOP at >30% of sites, PPD <4 mm and no radiographic evidence of bone loss; and (c) healthy subjects (n = 50) having <10% sites with BOP, and no sites with PPD >3 mm and CAL >4 mm. antibiotics, cholinergic therapies or anti-inflammatory medications within the last 3 months.
| Saliva and GCF collection
Unstimulated whole saliva was collected in the morning preceding all other assessments following an overnight fast during which subjects were requested not to drink (except water) or chew gum (Navazesh, 1993) . The saliva was centrifuged at 4000 g for 20 min at 20°C to remove debris and the supernatant stored at −80°C until required for analysis.
GCF was collected using Periopaper (OraFlow Inc., Smithtown, NY, USA) over 30 s as previously described ) from four sites per patient that were non-adjacent, had no endodontic involvement and were the deepest in each quadrant (sPPD, sCAL both >5 mm for periodontitis cases). The strips were pooled and the GCF eluted into 1 ml of phosphate buffered saline (PBS) containing 0.1%
(w/v) bovine serum albumin (BSA) and stored at −80°C until further analysis.
| Quantification of Acetylcholine levels in Saliva and gingival crevicular fluid
Levels of ACh were quantified using the Acetylcholine Assay Kit (Abcam, Cambridge, UK) in colorimetric assay mode as previously described (Reale et al., 2012) . Briefly, to determine total choline, 50 μl of saliva or GCF eluate was mixed with 50 μl of a reaction solution containing: choline assay buffer, choline probe, enzyme mix and acetylcholinesterase (AChE). Free choline was determined as above except for omitting the AChE. A standard curve was generated using a supplied choline standard. Each sample was analysed in triplicate.
The reactions were allowed to proceed for 30 min at room temperature in the dark and colorimetric changes at 570 nm read on a plate reader (BMG-Labtech, Ortenberg, Germany). Acetylcholine levels were determined using the following equation: Acetylcholine = Total choline -Free choline.
| Measurement of cholinesterase activity in saliva and GCF
Analysis of AChE and BChE activity levels was performed as described by Naik et al. (Naik, Liu, & Saxena, 2013) . Briefly, 10 μl of saliva or 20 μl of GCF was added to 50 mM sodium phosphate buffer, pH 8.0; 1.3 mM 5,5′-dithiobis(2-nitrobenzoic acid) (DTNB) and 20 mM ethopropazine or 500 nM huperzine A to a final volume of 250 μl. Following incubation at 22°C for 20 min, 50 μl of 6 mM Acetylthiocholine (ATC) or Butyrylthiocholine (BTC) was added and rates of ATC/BTC hydrolysis were obtained by reading the plates at 412 nm for 10 min. The rates of substrate hydrolysis were corrected for a 1 cm path length, dilution factor and an extinction coefficient of 14.15 × 10 3 M/cm for DTNB to obtain activity in units per ml (Eyer et al., 2003) . One unit (U) of enzyme activity is defined as the hydrolysis of 1 μM of substrate in 1 minute.
| Determination of cytokine and soluble receptor levels in saliva and GCF
Levels of IL-4, IL-6, TNF, IL-17A, IL-17F and IL-17E (all Peprotech, UK), IL-17A/F and IL-23R, (both R&D Systems, UK), TGF-β and IL-23
(both Mabtech, Sweden) were determined using commercially available ELISA kits as per the manufacturer's instructions. The limits of detection were determined as two mean standard deviations higher than the mean baseline from six replicate standard curves: IL-4, IL-6, TNF, IL-17A and IL-17F = 1.9 pg/ml; IL-17E = 3.8 pg/ml; IL-17A/F, IL-23R, TGF-β and IL-23 = 4.2 pg/ml. The IL-17A:IL-17E ratio was determined as previously described .
| Statistical analysis
A statistical power calculation was performed based on the assumption that the data were normally distributed (or log normally distributed) and that Central Limit Theorem applied. After adjusting α to 0.05/3 for the comparison of three groups and using effect sizes of 0.7 with parametric statistical tests the average numbers per group required to exceed 80% statistical power were n = 45.
Statistical analysis was performed using an ANOVA and a multivariate analysis in a General Linear Model. Adjustments were made for potential confounding factors such as age and smoking using least-square regression analysis. The figures show unweighted results; however, the statistical differences indicated reflect the results of the weighted analyses.
Associations between data were assessed using a Pearson correlation coefficient. All tests were performed at α = 0.05 significance level. Partial correlation analysis adjusting for age was used to explore potential associations. The large variation in cigarette usage meant partial correlation analysis correcting for smoking was statistically impossible. Therefore, analysis was also performed separately on the never smoker subjects to ascertain which associations remained after removal of smoking completely as a confounding factor. Table 1 shows the proportion of subjects who smoked was significantly greater in the gingivitis group and the periodontitis group compared to the healthy group (both p < 0.05). In addition, the cigarettes/day × year was significantly greater in the periodontitis group compared to the healthy group (p < 0.05). The age of the subjects was also significantly higher in the periodontitis group compared to the healthy group (both p < 0.001).
| RE SULTS
| Study population
All clinical parameters measured, after weighting for age and smoking status, were significantly greater in the gingivitis group and periodontitis group compared to the healthy group (all p < 0.001).
All clinical parameters measured except PI and sPI were significantly greater in the periodontitis group compared to the gingivitis group (all p < 0.001). Figure 1a shows that salivary levels of ACh were significantly elevated in the periodontitis group compared to the healthy group (p < 0.01) and the gingivitis group (p < 0.05). Figure 1b shows that GCF levels of ACh were significantly elevated in the periodontitis group compared to the healthy group (p < 0.001) and the gingivitis group (p < 0.001).
| Acetylcholine levels and cholinesterase activity in saliva and gingival crevicular fluid
No significant inter-group differences were observed with respect to salivary ( Figure 2a ) and GCF ( Figure 2b ) AChE activity and salivary BChE activity (Figure 2c ). However, GCF BChE activity was significantly decreased in the periodontitis (p < 0.01) and gingivitis group (p < 0.05) compared to the healthy group (Figure 2d ). Table 2A shows that salivary levels of IL-17A, IL-17A/F, IL-4 and the IL-17A:IL-17E ratio were significantly increased in the periodontitis group compared with the healthy group (all p < 0.01). Furthermore, salivary levels of IL-17A, IL-17A/F, and the IL-17A:IL-17E ratio were significantly increased in the periodontitis group compared to the gingivitis group (all p < 0.05). Table 2B shows that GCF levels of IL-17A, IL-17F, IL-17A/F and the IL-17A:IL-17E ratio were all significantly increased in the gingivitis group compared to the healthy group (all p < 0.05). GCF levels of IL-17A, IL-17F, IL-6 and the IL-17A:IL-17E ratio were all significantly increased in the periodontitis group compared to the healthy group (all p < 0.05). In addition, GCF levels of TGF-β are significantly decreased in the periodontitis group compared to the healthy group (p < 0.05). Furthermore, GCF levels of IL-17A, IL-17F and IL-6 were all significantly increased in the periodontitis group and IL-17A/F levels significantly decreased compared to the gingivitis group (all p < 0.05). never smokers (n = 94; all p < 0.05) were considered. Saliva AChE activity showed a moderate to strong significant positive correlation with BChE activity in all participants (p < 0.001) and never smokers (p < 0.001). Saliva BChE activity also showed a weak significant positive correlation with mean PD ≥5 mm in all participants (p < 0.05). Table 3B shows the major correlations between GCF levels of ACh, esterase activity and clinical parameters. The key findings are as follows: GCF levels of ACh had a weak significant positive correlation with BChE only when all participants were considered (all p < 0.01). GCF levels of ACh showed moderate to strong significant positive correlations with sBOP, sPI, sPPD and sCAL when all participants (n = 151; all p < 0.001) and never smokers (n = 94; all p < 0.001) were considered. A significant weak negative correlation between BChE activity and sBOP, sPPD and sCAL was also determined in all participants (all p < 0.01) and never smokers (all p < 0.05). Table 4A shows the major correlations between salivary levels of ACh, esterase activity and levels of selected inflammatory mediators. The key finding was that salivary levels of ACh had weak significant positive correlations with IL-17A and IL-17A/F when all participants were considered (both p < 0.05) but not in never smokers. Table 4B shows the major correlations between GCF levels of ACh, esterase activity and levels of selected inflammatory mediators. The key findings are as follows: GCF levels of ACh had moderate to strong significant positive correlations with IL-17A and IL-17F in all participants (both p < 0.001) and never smokers only (p < 0.001).
| Cytokine and soluble receptor levels in saliva and GCF
| Correlations between acetylcholine levels and esterase activity in saliva and GCF and clinical parameters
| Correlations between acetylcholine levels and esterase activity in saliva and GCF and levels of selected inflammatory mediators
F I G U R E 1 Saliva and gingival crevicular fluid levels of acetylcholine are upregulated in periodontal diseases.
Comparison of saliva (a) and gingival crevicular fluid (b) levels of ACh between healthy subjects, subjects diagnosed with gingivitis and subjects diagnosed with periodontitis. The statistical significances shown are following adjustment for age and smoking. *p < 0.05, **p < 0.01,***p < 0.01 F I G U R E 2 Gingival crevicular fluid butyrylcholinesterase activity is decreased in periodontal diseases.
Comparison of saliva (a) and gingival crevicular fluid (b) levels of AChE activity between healthy subjects, subjects diagnosed with gingivitis and subjects diagnosed with periodontitis. Comparison of saliva (c) and gingival crevicular fluid (d) levels of BChE activity between healthy subjects, subjects diagnosed with gingivitis and subjects diagnosed with periodontitis. The statistical significances shown are following adjustment for age and smoking. *p < 0.05, **p < 0.01, ***p < 0.01
ACh levels had a significant weak positive correlation with the IL-17A:IL-17E ratio and levels of IL-6 only when all participants were considered (both p < 0.01). GCF BChE activity showed significant weak negative correlations with levels of IL-17A and IL-17F in all participants (both p < 0.01) and never smokers (both p < 0.05). GCF BChE activity showed significant weak negative correlations with IL-17A/F in never smokers only (p < 0.01). GCF BChE activity showed significant weak negative correlations with the IL-17A:IL-17E ratio and levels of IL-6 in all participants only (both p < 0.05).
| D ISCUSS I ON
The data in this manuscript provide clinical evidence that cholinergic mechanisms may play a role in the pathogenesis of periodontal diseases. Significantly elevated levels of ACh are found in saliva and GCF of patients with gingivitis and periodontitis. Furthermore, GCF levels of ACh showed significant positive correlations with clinical parameters and levels of IL-17A and IL-17F. In contrast, GCF BChE activity is significantly decreased in patients with gingivitis and periodontitis and showed significant negative correlations with clinical parameters and levels of IL-17A and IL-17F.
A limitation of this study was the fact that smoking was not considered as an exclusion factor. Evidence suggests that smoking can impact on non-neuronal cholinergic mechanisms (Beckmann & Lips, 2013; Wessler, Kilbinger, Bittinger, Unger, & Kirkpatrick, 2003; Wessler & Kirkpatrick, 2008) . Furthermore, smoking has profound effects on the immune system (Qiu et al., 2017) and more specifically on IL-17 biology. Cigarette smoke extract and nicotine have been shown to downregulate Th17 responses (Peruzzo et al., 2016) .
Furthermore, IL-17 levels in GCF of gingivitis and periodontitis patients have been shown to be decreased in smokers compared to non-smokers (Buduneli, Buduneli, & Kutukculer, 2009; Peruzzo et al., 2016) . However, in this study, weighted analysis to correct for 
IL-23R
13.0 (6.7-19.2) 26.6 (15.5-37.7) 9.8 (−7.9 to 27.4)
Notes. The statistical analysis was weighted to correct for age and smoking. Statistical differences are highlighted in bold. *Significantly different from the healthy group. † Significant difference between periodontitis and gingivitis group. levels of inflammatory mediators remained significant when only never smokers were considered. Therefore, the evidence suggests that smoking status had little impact on the major findings reported.
TA B L E 3
The role of ACh as an anti-inflammatory neuroendocrine mediator has received a great deal of attention since the discovery of the cholinergic anti-inflammatory pathway (Borovikova et al., 2000) .
It is now well established that non-neuronal ACh, acting via the α7nAChR, can also negatively regulate proinflammatory mediator expression by both professional and non-professional immune cells (de Jonge et al., 2005; Macpherson et al., 2014; Yoshikawa et al., 2006) . However, evidence from in vivo and in vitro infection models suggests that it is too simplistic to state that within complex mucosal tissues ACh acts purely in an anti-inflammatory capacity (Giebelen, Leendertse, Florquin, & van der Poll, 2009; Giebelen et al., 2008; Rajendran et al., 2015) . There is indeed evidence to support a role for ACh in promoting neutrophil recruitment, activation and neutrophil extracellular trap (NET) formation (Carmona-Rivera et al., 2017; Giebelen et al., 2008; Rajendran et al., 2015; Ruhnau et al., 2014; Xu et al., 2008 (Buhling, Lieder, Kuhlmann, Waldburg, & Welte, 2007; Kawashima & Fujii, 2004) and in vivo (Kistemaker et al., 2013; Mclean et al., 2016) .
It is now evident that numerous immune cells express ChAT including T cells, B cells, dendritic cells and macrophages (Fujii et al., 2017) . Evidence suggests that T and B cells can acquire the ability to produce ACh in the mucosa-associated lymphoid tissue (MALT) prior to emigration to peripheral sites (Reardon et al., 2013) . Interestingly,
ChAT expression by B and T cells is hypothesised to be dependent on the establishment of the host microbiota and occurs in response to Toll-Like Receptor (TLR) agonists (Friswell et al., 2010; Reardon et al., 2013) . Furthermore, evidence suggests that the ability of immune cells to express ChAT is in fact transient and not lineage specific (Reardon et al., 2013) . Immune cells, like neurons, have been shown to synthesise and store ACh. In T and B cells, the actual release of ACh has been found to be regulated by Norepinephrine and Cholecystokinin, respectively (Reardon et al., 2013; Rosas-Ballina et al., 2011) . Furthermore, ChAT + T cells and ChAT + B cells have been shown to have differential immunomodulatory functions (Reardon et al., 2013) . Moreover, there is now evidence for ChAT + T cells with characteristics of both Treg (Reardon et al., 2013) and Th17 cells (Dhawan et al., 2016) . Interestingly, ChAT of the gut microflora (Dhawan et al., 2016) . Therefore, ACh may not only regulate the host response to complex multispecies biofilms but also influence biofilm composition directly therefore having much more complex roles in biofilm driven inflammatory diseases such as periodontal diseases.
Extracellular ACh is extremely labile due to the action of esterases (Wessler et al., 2003) . The amount of available ACh within tissues is therefore modulated by a careful balance of synthesis and degradation. In humans, the principle cholinesterases are AChE and BChE (Wessler & Kirkpatrick, 2008) . Although AChE is thought to be principally membrane bound, there is evidence that within some tissues, including the neuromuscular junction and brain, a soluble form exists (Hicks et al., 2011) . In contrast, the presence of both membrane bound and soluble forms of BChE in humans is well documented (Darvesh, Hopkins, & Geula, 2003) . Evidence has shown that perturbations in BChE activity are associated with diseases with an inflammatory component (Darvesh et al., 2003) . For example, serum BChE activity levels are reduced in sterile inflammatory responses to surgery and in response to traumatic injury (Zivkovic, Bender, Brenner, Hofer, & Schmidt, 2016; Zivkovic et al., 2017) .
Moreover, genetic variations in BChE have been associated with autoimmune diseases such as arthritis and multiple sclerosis (Reale et al., 2018; Shahmohamadnejad et al., 2015) . 
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